Stocks of Iovance Biotherapeutics Inc (NASDAQ:IOVA) traded higher last session on Wall Street, up 10.24% to $1.83.
IOVA stock price is now -42.15% away from the 50-day moving average and -74.31% away from the 200-day moving average. The market capitalization of the company currently stands at $611.10M.
With the price target maintained at $2, UBS recently Downgraded its rating from Buy to Neutral for Iovance Biotherapeutics Inc (NASDAQ: IOVA). , while ‘Citizens JMP’ rates the stock as ‘Mkt Perform’
In other news, Vogt Frederick G, Interim CEO & General Counsel bought 25,000 shares of the company’s stock on May 14 ’25. The stock was bought for $42,250 at an average price of $1.69. Upon completion of the transaction, the Interim CEO & General Counsel now directly owns 374,646 shares in the company, valued at $0.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 12 ’24, Director Maynard Ryan D sold 50,000 shares of the business’s stock. A total of $503,000 was realized by selling the stock at an average price of $10.06. This leaves the insider owning 7,500 shares of the company worth $13725.0. A total of 18.66% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $1.64 and a high of $12.51. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.18, and a quick ratio of 3.64.
The net profit margin was -176.49% and return on equity was -51.85% for IOVA. For the current quarter, analysts expect IOVA to generate $66.65M in revenue.
